Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2016 - 2021)

Historic Liabilities and Shareholders Equity for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $2.0 billion.

  • Neurocrine Biosciences' Liabilities and Shareholders Equity rose 3425.4% to $2.0 billion in Q3 2021 from the same period last year, while for Dec 2021 it was $5.8 billion, marking a year-over-year decrease of 481.95%. This contributed to the annual value of $1.7 billion for FY2020, which is 3282.54% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Liabilities and Shareholders Equity is $2.0 billion, which was up 3425.4% from $2.0 billion recorded in Q2 2021.
  • Neurocrine Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $2.0 billion during Q3 2021, with a 5-year trough of $289.4 million in Q1 2017.
  • Its 5-year average for Liabilities and Shareholders Equity is $1.2 billion, with a median of $1.1 billion in 2019.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 3700.33% in 2017, then skyrocketed by 17866.63% in 2018.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Liabilities and Shareholders Equity stood at $817.6 million in 2017, then grew by 21.47% to $993.2 million in 2018, then surged by 31.5% to $1.3 billion in 2019, then skyrocketed by 32.83% to $1.7 billion in 2020, then grew by 16.29% to $2.0 billion in 2021.
  • Its last three reported values are $2.0 billion in Q3 2021, $2.0 billion for Q2 2021, and $1.8 billion during Q1 2021.